We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -186.00 | -1.58% | 11,600.00 | 11,592.00 | 11,596.00 | 11,684.00 | 11,500.00 | 11,600.00 | 4,434,420 | 16:35:25 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8406 | 30.19 | 182.75B |
From Feb 2020 to Feb 2025
LONDON--AstraZeneca PLC (AZN.LN) said Friday it got approval for ZS-9, its drug against hyperkalaemia, from the committee for medicinal products for human use of the European medicines agency.
Hyperkalaemia is a condition characterized by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic diseases.
Shares at 1245 GMT down 22 pence, or 0.5%, at 4578.5 pence valuing the company at GBP57.93 billion.
-Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
February 24, 2017 08:02 ET (13:02 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
